Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 47%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is experiencing a positive outlook driven by its innovative therapeutic candidates, particularly BT8009 and BT5528, which have demonstrated promising efficacy and acceptable safety profiles in clinical trials for high-unmet-need indications such as urothelial and ovarian cancer. The company has enhanced its probability of success for BT8009 to 40% in various treatment settings, which bolsters its overall platform value and reflects confidence in its clinical development pipeline. Furthermore, the company's efficient drug selection process through its high throughput phage display screening platform positions it favorably within the competitive landscape, suggesting potential differentiation from existing therapies like Padcev.

Bears say

Bicycle Therapeutics PLC faces significant financial challenges, as highlighted by its bear case scenario indicating a potential 0% success rate for its product candidate BT8009, which could lead to a drastic reduction in platform value and a fair value of $9 per share based solely on cash. The company has reported disappointing clinical data for key oncology indications, while elevated selling, general, and administrative expenses of $21.6 million exceeded both internal and consensus estimates, further straining financial resources. Additionally, regulatory and commercial risks loom large, as the company's clinical assets could fail to demonstrate sufficient efficacy or safety, hindering approval timelines and diminishing sales potential amidst increasing competition.

BCYC has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 47% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 17 analysts, BCYC has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.